Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab)…
Oncology
-
-
Daiichi Sankyo, MSD withdraw cancer drug application
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at…
-
Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
Innovent Biologics has announced an expansion of its global Phase III MarsLight-11 trial evaluating IBI363, also known as TAK-928, to…
-
Orum to begin Phase I trial of ORM-1153 after FDA clearance
The US Food and Drug Administration (FDA) has approved Orum Therapeutics' investigational new drug (IND) application for ORM-1153, a new…
-
Johnson & Johnson’s multiple myeloma treatment secures EC approval
The European Commission (EC) has approved an extended use of Johnson & Johnson's Tecvayli (teclistamab), along with daratumumab, to treat…
-
FDA issues complete response letter to Replimune’s RP1 for melanoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application…
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of…
-
North Oaks opens new speciality services clinic in US
The North Oaks Health System has opened a new $50m, five-storey speciality services clinic in Hammond, Louisiana, US. The new…
-
New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in…
-
NCCN visits Vietnam in continued cancer care collaboration
Leaders from the National Comprehensive Cancer Network (NCCN) alliance of US cancer centres are in Vietnam today (1 November) as…
